This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Lannett Reports Fiscal 2012 Second Quarter Financial Results

Lannett Company, Inc. (NYSE AMEX:LCI) today reported financial results for the fiscal 2012 second quarter and six months ended December 31, 2011.

For the second quarter of fiscal 2012, net sales were $27.7 million and net income attributable to Lannett Company was $609,000, or $0.02 per diluted share. The fiscal 2012 second quarter results were negatively impacted by a $945,000 reduction in sales, related to the recently enacted federal Patient Protection and Affordable Care Act (PPACA). For the second quarter of the prior year, net sales were $30.0 million and net income attributable to Lannett Company was $2.4 million, or $0.09 per diluted share. Last year’s fiscal second quarter results benefited from sales of OB Natal ® One Tablets, a product the company no longer markets, a reversal of royalty expense related to this product and certain non-operating items, which totaled approximately $0.03 per diluted share.

“Recently approved products were the key drivers for our solid fiscal 2012 second quarter financial performance,” said Arthur Bedrosian, president and chief executive officer of Lannett. “Without the impact of the PPACA, net sales, gross profit and operating income were comparable to our fiscal 2012 first quarter results. Our momentum has continued into January 2012 with two additional product approvals, bringing to nine the total number of approvals we have received in the last seven months. This adds to our belief that the second half of our fiscal year will show further improvement.”

For the fiscal 2012 second quarter, gross profit was $7.4 million compared with $8.4 million for the same period in the prior year. Research and development (R&D) expenses were $2.5 million compared with $1.7 million in the fiscal 2011 second quarter. Selling, general and administrative (SG&A) expenses were $4.4 million compared with $2.9 million in the same quarter of the prior year. Operating income was $495,000 compared with $3.8 million for the second quarter of fiscal 2011.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs